Labels: sources manual selection automatic selection
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were developed as insulinotropic and anti-hyperglycemic agents for the treatment of type 2 diabetes, but their neurotrophic and neuroprotective activities have been receiving …
Continue Reading
Multiple sclerosis (MS), an immune-mediated and neurodegenerative disorder of the central nervous system (CNS), is characterized by infiltrating myelin-reactive T lymphocytes and demyelinating lesions. Experimental autoimmune …
Continue Reading
Fingolimod (FTY720) is an oral drug approved by the Food and Drug Administration (FDA) for management of Multiple Sclerosis (MS) symptoms, which has also shownbeneficial effects against Alzheimer’s (AD) and Parkinson’s (PD) …
Continue Reading
Infection in people with multiple sclerosis (MS) is of major concern, particularly for those receiving disease-modifying therapies. This article explores the risk of infection in people with MS and provides guidance-developed by …
Continue Reading
Fingolimod, used to treat relapsing-remitting multiple sclerosis (RRMS), reduces motor deficits in mice with established experimental autoimmune encephalomyelitis (EAE). To better characterize the therapeutic effects of …
Continue Reading
CONCLUSION: Physiotherapy interventions are feasible for mobility in severe MS. There is some evidence for the effectiveness of RAGT.
Continue Reading
CONCLUSIONS: Our findings do not support the hypothesis that the introduction of novel DMT for MS has reduced the incidence of epilepsy among MS patients.
Continue Reading
Osteoporosis and multiple sclerosis are highly prevalent diseases with limited treatment options. In light of these unmet medical needs, novel therapeutic approaches are urgently sought. Previously, the activation of the …
Continue Reading
Articles listed here come from the following sites, with keyword searches for Multiple Sclerosis, autoimmune encephalomyelitis, encephalomyelitis, immune tolerance, myelin.